Renal care companies develop business through vertical integration and innovative home care products
This article was originally published in Clinica
Although dialysis technology has changed little over the years, companies are constantly developing new treatment techniques and solutions as the number of people suffering from end-stage renal disease (ESRD) continues to climb by an annual average of 8%. Some 800,000 people worldwide require dialysis treatment making a product market of about $6 billion with the cost of treatments worth approximately $23 billion, according to a new report published by Theta Reports, entitled Kidney dialysis equipment & supplies.
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.